Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Is Abbott's January Pullback a Good Time to Buy? By Thomas Hughes. Publication Date: 1/24/2026. 
Key Takeaways - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback has made the stock look more attractively valued. The move—driven more by market angst than by any material company weakness—appears to be a knee-jerk overreaction that has pushed the shares back into a potential buy zone. 
The zone lines up with market action from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates The most that can be said about Abbott Laboratories' Q4 results and guidance is that a few metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year-over-year, margins improved, and adjusted earnings grew at an accelerated pace. Revenue growth missed by several hundred basis points, but margin strength helped compensate: adjusted earnings per share (EPS) rose about 12%, slightly above consensus. Segment results illustrated the benefits of Abbott’s diversified healthcare portfolio. Nutrition and Diagnostics contracted—Nutrition declined nearly 9%—but those declines were offset by solid gains in Established Pharmaceuticals and Med Tech. The pharma segment grew roughly 9%, driven by generics and emerging markets, while Med Tech expanded about 12.3% with broad-based strength across sub-segments. Margins improved but came in a bit below some analyst forecasts. A favorable product mix, strength in Med Tech, reduced COVID-19-related sales and operational improvements all supported margins, and management expects improvement to continue. The company projects earnings growth of about 10% in 2026—outpacing revenue growth—and enough cash generation to sustain its capital return plans. Abbott’s capital returns are a key part of the investment case. The company is a Dividend King, having raised its payout for more than 50 consecutive years, and it appears positioned to continue doing so. After the pullback the stock yields roughly 2.5%, and Abbott pays out less than half of consensus earnings, leaving ample cash flow for share buybacks—an important offset to the dilutive effects of share-based compensation. Analysts See Robust Upside Potential Some analysts noted the revenue miss, but there were no major rating changes or widespread target cuts on the morning of the earnings release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth, and the growth runway remains meaningful. The MarketBeat consensus share price target implies the stock could rebound as much as 30%, potentially reaching new all-time highs; even the low-end targets suggest upside from current levels. Key catalysts include expansion in Med Tech, AI integration across operations and products, margin expansion and strategic acquisitions. The deal for Exact Sciences, for example, broadens Abbott's revenue and profit streams and diversifies its product pipeline. That said, the recent sell-off has left the share price vulnerable to further declines. Institutions accumulated shares through 2025 and are likely interested buyers at discounted prices, providing some support. Early technical support appears around $105 to $110, but that level is not yet confirmed. The risk remains that ABT could drift down to the low end of a buy zone—and potentially toward the mid-to-high $90s—before staging a sustainable rebound.
| 
